MAIA Biotechnology (NYSE:MAIA) shares rose Tuesday after the clinical-stage company outlined an aggressive roadmap for its telomere-targeting immunotherapy, projecting a potential path to commercial approval within 18 to 24 months.
The Chicago-based biotech, which is developing ateganosine (THIO) for advanced non-small cell lung cancer (NSCLC), highlighted a transformative 2025 that saw the initiation of its pivotal THIO-104 Phase 3 trial.
The company enters 2026 with significant momentum following a $2.3 million NIH grant and strategic partnerships with industry leaders Roche and BeOne.
Efficacy data from its ongoing Phase 2 trials showed a median overall survival of 17.8 months—nearly triple the current standard of care—positioning the drug for potential Accelerated Approval by the U.S. FDA.
"MAIA’s strong clinical execution in 2025 delivered exceptional efficacy data that clearly differentiates our novel telomere-targeting science," said CEO Vlad Vitoc, M.D.
The company, which raised $17.6 million in capital last year, plans to provide interim Phase 3 efficacy readouts in 2026.
If successful, ateganosine would become the first-ever telomere-targeting agent to reach the market, addressing a massive unmet need for third-line lung cancer patients who have failed prior chemotherapy and immunotherapy.